ABEONA THERAPEUTICS INC. (ABEO) stock intrinsic value fair value estimate & owner earnings analysis

Abeona Therapeutics is a Cleveland-based gene-therapy company with one product, ZEVASKYN, approved by the FDA in April 2025 for wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe inherited skin-blistering disease. Each treatment is a one-time, patient-specific graft of gene-corrected skin sheets made at the company's single manufacturing site in Cleveland and applied at a hospital. Four hospitals are activated (Lurie Children's in Chicago, Stanford, Children's Hospital Colorado and UTMB Galveston), every state Medicaid program covers the therapy, and a permanent billing code took effect January 1, 2026. The company's own claims analysis points to roughly 750 moderate-to-severe patients in the U.S. The data-exclusivity period for the product runs 12 years from approval, to about April 2037. A competing topical gene therapy, Krystal Biotech's Vyjuvek, has been on the market since 2023. What the numbers show. Product sales were $2.4 million in 2025 (the first patient was treated in December), then $8.7 million in the first quarter of 2026 and $11.4 million in the second. At roughly $2.85 million of net revenue per treatment (we infer treatment counts from revenue; they are not broken out in the filings we used), that is about 3 treatments in the first quarter and 4 in the second. Gross margin was about 63% in the second quarter, because manufacturing costs are still largely fixed. Costs remain heavy: research and development of $26.8 million and selling and administrative costs of $65.0 million in 2025, with the second-quarter operating loss narrowing to $13.7 million from $23.0 million in the first quarter. The cash left for owners after equipment spending and the cost of shares issued to employees has been negative every year, about -$84 million in 2025 (-$1.59 per share, versus -$1.48 in 2024). Because losses are deepening in total while the share count grows, we do not treat any past earnings level as a base for the future; each case is built from the current run rate instead. We exclude the $152 million gain on the 2025 sale of the priority review voucher, which was a one-time asset sale and not operating cash. Employee share awards (about $11 million in 2025) are counted as a real cost. Revenue in 2025 also included about $3.4 million of license and other income that we do not expect to recur. Balance sheet. At June 30, 2026 the company held $146.8 million of cash and short-term investments and owed about $15.4 million to its secured lender (a fixed 11.75% term loan, repaid in monthly installments that began in February 2026, with the balance and a $1 million final fee due July 1, 2027, and a requirement to keep at least $5 million of cash). We charge about $15.8 million for the debt including the above-market interest. The company states its cash covers at least twelve months of spending and the auditors raise no going-concern doubt. Even in the weakest case below, cash comfortably covers the loan repayment and the covenant. The loan holder can convert up to $3 million into shares, and the company has an at-the-market stock program, so further dilution is a real possibility that our cases do not model. Growth credited and left out. Only two quarters of sales exist, so we credit growth only where it has already been demonstrated or is a feature of the case's named drivers. The base case credits holding the second-quarter pace (about 16 treatments a year) and nothing more; ramping new hospitals, winning more patients, and falling manufacturing cost per treatment are left out of the base because none has been shown to repeat. The bull case credits what has happened once (treatments rising by about one per quarter) continuing for about four years to roughly 80 a year, then declining as the identified patient pool is worked through, with gross margin rising to 70% on the manufacturing capacity already built. We left out price increases, label expansions, the earlier-stage vision-disease candidate ABO-503 and anything after exclusivity ends. Bear case: $0.36 per share. Experience with other one-time gene therapies, which have often sold at a small fraction of plan for years, is the named precedent. Treatments stall at about 12 a year (the first-quarter pace) and the company keeps its present cost base until mid-2027 before cutting. At that volume gross profit of about $21 million cannot support even a slimmed company, so the story ends with a wind-down in 2029. Cumulative losses and wind-down costs of about $110 million (present value) against $146.8 million of cash and $15.8 million of debt leave roughly $21 million, or $0.36 per share on about 58 million shares. The business is worth about -$110 million, it owes $15.8 million, and cash of $146.8 million covers the difference. Base case: $1.06 per share. Treatments hold at about 16 a year (about $45 million of annual sales) and management trims costs through 2027, as the company's filing says it has the flexibility to do, to a level the product can carry by 2028. The franchise at that size roughly breaks even, so we assign it no value beyond cash. Losses and restructuring of about $61 million (present value) are paid from the $146.8 million of cash, after $15.8 million of debt, leaving about $70 million, or $1.06 on roughly 66 million diluted shares. The business is worth about -$61 million, it owes $15.8 million, and cash of $146.8 million covers both. Bull case: $3.30 per share. Treatments climb to about 34 in 2027, 50 in 2028 and 79 in 2030, then decline from 2031 as eligible patients are treated (about 600 patients in total, most of the identified pool). Losses of about $65 million (present value) continue through 2028, then profits reach roughly $50 million a year in 2030 and 2031 (sheltered by about $311 million of tax losses, subject to the 80% limit) before fading as volume falls; nothing is credited after 2034. The business is worth about $87 million, it owes $15.8 million and holds $146.8 million of cash, leaving about $218 million, or $3.30 on 66 million shares. Why the outcomes spread so widely. Everything rides on one product made at one site and sold through four hospitals, and the year-one improvement we assume in the base (a loss of about $56 million a year, versus $84 million in 2025) rests on the specific second-quarter 2026 result: operating loss of $13.7 million against $23.0 million in the first quarter and $22.8 million a year earlier. We tested the case against two facts: gross profit at 16 treatments (about $29 million) cannot cover today's roughly $85 million of annual costs, so spending must fall or volume must rise; and break-even in the bull case needs close to 50 treatments a year, three times the current pace. If we are wrong about volume by even a few treatments a quarter, or if costs are not trimmed as assumed, each extra $10 million of annual loss removes about $0.15 per share. Margin-of-safety price: $0.60. We are not sure of the earnings level: the launch is two quarters old, treatment counts are inferred, and the company has never produced positive operating cash flow. The worst plausible event is a manufacturing or safety problem at the single Cleveland plant, or hospitals declining to treat; that could halt sales while costs continue. The structure would survive it for roughly two to three years, because net cash of about $131 million exceeds the debt and the loan is secured and small, but equity could be left with little after a prolonged halt, and the at-the-market program means a bad stretch is likely to be funded by selling shares. If the two things we are most likely wrong about, volume (stuck near 12 a year) and the ability to cut costs, both turn out unfavourably, the shares are worth roughly the bear figure. The company pays no dividend, so returns come only from the business reaching self-sufficiency; the price assumes a two-to-four-year holding period to see whether quarterly treatments move past about 10. The margin-of-safety price is $0.60 because at that price the whole company would be valued at less than half of the cash it is expected to still hold in the slow-launch path after repaying its debt, which leaves room for a 20% annual return if volume merely holds at the second-quarter pace and for losses if the launch fails. Our August 2026 estimates assumed a steady climb to 60 to 100 treatments a year; they were built on a different basis and are not comparable to these.